BMO Capital Markets Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by BMO Capital Markets from $135.00 to $150.00 in a research note issued to investors on Monday, MarketBeat Ratings reports. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on GILD. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Scotiabank initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Wolfe Research reissued an “outperform” rating and set a $150.00 target price on shares of Gilead Sciences in a research note on Monday, December 15th. Finally, Morgan Stanley lowered their price target on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $134.52.

Gilead Sciences Stock Up 1.4%

Shares of NASDAQ:GILD opened at $137.78 on Monday. The firm has a 50 day simple moving average of $124.25 and a 200 day simple moving average of $118.88. Gilead Sciences has a 52 week low of $93.10 and a 52 week high of $138.03. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company has a market cap of $170.94 billion, a PE ratio of 21.36, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This represents a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 247,397 shares of company stock valued at $31,986,612 in the last three months. 0.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $2,150,268,000. Ameriprise Financial Inc. lifted its position in Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after acquiring an additional 4,113,999 shares during the period. Invesco Ltd. boosted its holdings in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.